Bioinformatics News

Biology’s next great horizon is to understand cells, tissues and organisms as agents with agendas (even if unthinking ones)

Insilico proudly presents the "Best Editing" of the Docuthon competition. "I used to work in the traditional pharmaceutical industry in the lab doing DNA extraction with physical methods before switching to editing. Docuthon has been an inspiring experience. In recent years, generative AI has become the elephant in the room, and Insilico Medicine has kept abreast of the times and successfully combined artificial intelligence with drug discovery to address the pain points of traditional pharmaceuticals. I’m from the same town as Dr. Ren, and it made me feel proud to witness their significant contributions to the advancement of drug development for the benefit of our community."

Insilico presents their in-house participation in the Docuthon contest. The creator, Larry Zhang, is responsible for the entity's video content. "As a filmmaker and artist, I once perceived science as confined to numbers and calculations, lacking in the exploration of dreams, emotions, and romance. However, as I sifted through the footage, I discovered that experts in AI and drug development possess even more curiosity, creativity, and passion to their craft. The success of Insilico Medicine isn’t solely attributed to the advancement of AI. it’s the individuals collaborating, imagining, leaping without safety ropes who bridged the gap between a novel technology and a finely tuned methodology. As I delved deeper into crafting the story, I came to realize that generative AI serves as the nexus where art and science converge from opposite ends of a circular spectrum. The overarching concept revolves around utilizing AI to heal humanity and extend healthy longevity."

Michael Levin is an American developmental and synthetic biologist at Tufts University, where he is the Vannevar Bush Distinguished Professor. Levin is a director of the Allen Discovery Center at Tufts University and Tufts Center for Regenerative and Developmental Biology. He is also co-director of the Institute for Computationally Designed Organisms with Josh Bongard. Listen on Spotify:

Join TOEmail at

Links Mentioned: Michael’s paper on cognition -

Gabriele Carcassi Video -

Michael Levin’s blog post on advice -

TOE ep with Levin, Tung and Gumuskaya -

TOE ep with Levin -

TOE ep with Bach and Levin -

TOE ep with Lang, Friston and Levin -

TOE ep with Iain McGilchrist -

Timestamps: 00:00 - Intro 00:30 - Biggest Myths of Biology 07:18 - Tying Michael's Work Together 35:25 - Who Are We (Humans)? 56:10 - Cognition 01:14:10 - Conscious Agents 01:33:25 - Bioelectricity and Cancer 02:16:15 - Support TOE Support TOE: - Patreon:

(early access to ad-free audio episodes!) - Crypto:

- PayPal:

- TOE Merch:

Follow TOE: - NEW Get my 'Top 10 TOEs' PDF + Weekly Personal Updates:

- Instagram:

- TikTok:

- Twitter:

- Discord Invite:

- iTunes:

- Pandora:

- Spotify:

- Subreddit r/TheoriesOfEverything:

Join this channel to get access to perks:

#science #biology

This episode of Longevity by Design discusses groundbreaking research on the use of gene therapies to target common diseases of aging. Dr. Noah Davidsohn leverages genes associated with aging as targets for de-aging cells and reducing the burden of age-related diseases. The research appears promising—Dr. Davidsohn is confident that these findings will eventually improve human lifespan and healthspan. Tune in for conversations that dissect the latest research in the field of longevity.  For science-backed ways to live a healthier longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast 0:00 Introduction 2:00 Background on Dr. Davidsohn 5:42 What is epigenetics?  6:32 What makes epigenetics modifiable? 8:00 What are Yamanaka factors? 11:25 Deaging a cell without losing cell identity  12:00 Landmark paper rejuvenating mice 14:00 Inducing Yamanaka factors 17:00 Applying findings from Yamanka factors 18:30 Gene therapies to target healthspan 19:52 Targeting age-related diseases 26:14 Aging of dogs 31:18 Is aging a disease? 34:29 Early research insights 37:32 Top tip for healthspan To learn more:

— Let’s Connect! Instagram -

Twitter -

Facebook -

LinkedIn-

  TikTok-

  Pinterest-

  Website -

  In the Press -

Combination gene therapy developed at Wyss Institute and Harvard Medical School treats four age-related conditions